Stock listing

OTC:WINT Windtree Therapeutics, Inc. Stock

Follow Windtree Therapeutics, Inc. into a list and get an email when it puts out news.

Windtree Therapeutics, Inc. logo
Ticker
OTC:WINT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

Windtree Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
Decks
37 decks · latest Oct 1, 2024

Valuation

balance Sep 30, 2025

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
0.57

Events

QuarterResults
Q3 2025Nov 19, 2025
Q2 2025Aug 19, 2025
Q1 2025May 13, 2025 · After close
Q3 2024Nov 26, 2024 · After close
Q2 2024Aug 19, 2024 · After close
Q1 2024May 15, 2024 · After close
Q4 2023Mar 29, 2024 · After close
Q3 2023Nov 9, 2023 · After close
Q2 2023Aug 7, 2023 · After close
Q1 2023Apr 3, 2023 · Before open
All 19 quarters
QuarterResults
Q4 2022Mar 31, 2023 · After close
Q3 2022Nov 14, 2022 · Before open
Q2 2022Aug 11, 2022 · After close
Q1 2022May 5, 2022 · After close
Q4 2021Mar 31, 2022 · Before open
Q3 2021Nov 10, 2021 · After close
Q2 2021Aug 5, 2021 · After close
Q1 2021May 13, 2021 · Before open
Q4 2020Mar 29, 2021 · After close

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2024)Investor deck38 slidesOct 1, 2024
Investor Presentation (September 2024)Investor deck32 slidesSep 13, 2024
Investor Presentation (July 2024)Investor deck32 slidesJul 3, 2024
Investor Presentation (November 2023)Investor deck31 slidesNov 9, 2023
Investor Presentation (September 2023)Investor deck31 slidesSep 26, 2023
Investor Day (June 2023)Investor day42 slidesJun 14, 2023
Investor Presentation (April 2023)Investor deck37 slidesApr 3, 2023
Investor Presentation (November 2022)Investor deck42 slidesNov 14, 2022
Investor Presentation (August 2022)Investor deck42 slidesAug 11, 2022
Investor Presentation (July 2022)Investor deck42 slidesJul 18, 2022
All 37 decks
DeckKindSlidesDate
Investor Presentation (June 2022)Investor deck41 slidesJun 6, 2022
Investor Presentation (May 2022)Investor deck27 slidesMay 23, 2022
Investor Presentation (May 2022)Investor deck47 slidesMay 5, 2022
Investor Presentation (April 2022)Investor deck46 slidesApr 20, 2022
Investor Presentation (March 2022)Investor deck44 slidesMar 31, 2022
Investor Presentation (October 2021)Investor deck44 slidesOct 18, 2021
Investor Presentation (September 2021)Investor deck43 slidesSep 20, 2021
Investor Presentation (August 2021)Investor deck45 slidesAug 5, 2021
Investor Presentation (May 2021)Investor deck44 slidesMay 13, 2021
Investor Presentation (February 2021)Investor deck44 slidesFeb 19, 2021
Investor Presentation (November 2020)Investor deck43 slidesNov 16, 2020
Investor Presentation (August 2020)Investor deck41 slidesAug 20, 2020
Corporate Update (June 2020)Corporate update42 slidesJun 4, 2020
Investor Presentation (May 2020)Investor deck41 slidesMay 7, 2020
Investor Presentation (December 2019)Investor deck30 slidesDec 11, 2019
Investor Presentation (October 2019)Investor deck39 slidesOct 25, 2019
Corporate Update (January 2019)Corporate update39 slidesJan 3, 2019
Investor Presentation (August 2018)Investor deck42 slidesAug 27, 2018
Investor Presentation (February 2018)Investor deck46 slidesFeb 27, 2018
Investor Presentation (January 2018)Investor deck38 slidesJan 8, 2018
Corporate Update (November 2017)Corporate update14 slidesNov 1, 2017
Corporate Update (June 2017)Corporate update22 slidesJun 30, 2017
Corporate Update (October 2016)Corporate update37 slidesOct 25, 2016
Discovery Laboratories — Investor Presentation (April 2016)Investor deck31 slidesApr 18, 2016
Discovery Laboratories — Corporate Update (November 2015)Corporate update33 slidesNov 12, 2015
Discovery Laboratories — Corporate Update (October 2013)Corporate update16 slidesOct 17, 2013
Discovery Laboratories — Corporate Update (October 2012)Corporate update18 slidesOct 24, 2012

Open Decks

Financials

Annual, in USD

Income statement

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue00000198.0K1.79M1.49M2.04M987.0K
Cost of revenue84.0K82.0K1.06M869.0K638.0K12.7K10.6M17.4M255.0K929.0K
Gross profit-84.0K-82.0K-1.06M-869.0K-638.0K185.3K-8.77M-15.9M1.79M58.0K
Research and development16.3M8.26M11.1M17.8M15.4M12.7M10.6M17.4M31.7M28.9M
Selling, general and administrative8.74M8.70K10.8M14.5M14.9M12.4M7.42M6.66M7.17M11.0M
Operating income-25.0M-17.5M-41.3M-77.3M-30.3M-24.9M-16.2M-22.5M-38.0M-39.8M
Depreciation and amortization84.0K82.0K533.0K192.0K168.0K195.0K159.0K192.0K255.0K712.0K
EBITDA-24.9M-17.5M-40.8M-77.1M-30.1M-24.7M-16.0M-22.4M-37.8M-39.1M
Interest expense235.0K50.0K53.0K114.0K125.0K495.0K1.41M1.86M2.52M4.58M
Income before tax-1.79M-20.3M-40.6M-77.6M-32.6M-27.5M-20.5M-18.4M-39.5M-55.2M
Income tax3.69M-85.9K-1.37M-9.99M-2.29M2.39M-2.93M1.99M1.20M4.67M
Net income-5.49M-20.3M-39.2M-67.6M-30.3M-27.5M-20.5M-18.4M-39.5M-55.2M
Earnings per share, basic-104.35-4,712.26-125.71-685.51-2,691.67-14,230.63-23,759.69

Balance sheet

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash and equivalents1.78M4.32M6.17M22.3M16.9M22.6M11.2M1.81M5.59M38.7M
Short-term investments014.0M
Current assets2.57M5.38M7.38M23.5M18.1M23.9M25.7M2.24M7.19M40.8M
Property, plant and equipment3.39M1.84M798.0K802.0K885.0K1.05M1.04M
Goodwill03.06M15.7M15.7M15.7M15.7M
Total assets27.9M32.4M38.0M74.8M112.9M119.0M119.4M3.35M9.70M44.4M
Accounts payable1.88M809.0K249.0K693.0K1.16M1.71M3.42M3.05M1.81M3.26M
Current liabilities5.72M4.00M2.46M4.92M6.13M7.82M20.6M11.8M13.4M11.1M
Long-term debt2.42M4.61M15.0M15.0M25.0M25.0M
Total debt1.82M16.8M2.28M2.89M3.78M20.5M23.0M15.0M25.0M25.2M
Total liabilities17.9M29.0M27.9M32.9M43.3M44.0M51.3M27.3M38.5M36.1M
Shareholders' equity10.00M3.39M10.0M41.9M69.6M74.9M68.1M-23.9M-28.8M8.27M
Shares outstanding52.6K4.31K700550348218.6K30.0K6.85K2.77K2.32K

Cash flow

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations-15.4M-13.4M-19.5M-23.7M-25.3M-24.7M-15.8M-21.0M-33.6M-33.5M
Capital spending-12.0K-15.0K-13.0K-279.0K-291.0K-191.0K-9.00K-24.0K-281.0K-458.0K
Free cash flow-15.4M-13.5M-19.5M-23.9M-25.6M-24.9M-15.8M-21.1M-33.9M-34.0M
Cash from investing-12.0K-15.0K197.0K-279.0K-291.0K13.8M-13.7M-24.0K-254.0K-188.0K
Cash from financing12.7M11.6M3.08M29.4M20.0M21.8M38.7M17.3M709.0K27.7M
Dividends paid-657.0K0-151
Share buybacks-1.88M020.4M-15132.9M1.04M709.0K32.8M
Change in cash-2.68M-1.86M-16.2M5.42M-5.65M11.4M9.32M-3.77M-33.1M-5.99M

Open Financials

Cap table

Built by 6ix from Windtree Therapeutics, Inc.’s releases

Common shares
33,708,784
Fully diluted
33,708,784

Fully diluted

LineShares
Common shares33,708,784

Share count over time

CountShares
Nov 22, 202633,708,784

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Bruce Peacock
Other companies: Dicerna Pharmaceuticals Inc (Director · Sep 9, 2014 – Jul 18, 2017 · Past); Ocular Therapeutix, Inc. (Director · Jul 24, 2014 – Jun 18, 2021 · Past); IVERIC bio Inc (CFO & CBO · Sep 24, 2013 – Sep 2, 2014 · Past); Ocean Power Technologies, Inc. (Director · Oct 6, 2011 – Oct 4, 2012 · Past); Ligand Pharmaceuticals Incorporated (Director · Dec 23, 2008 – Dec 23, 2008 · Past); NeurogesX Inc (Director · Aug 30, 2007 – May 28, 2009 · Past); Pharmacopeia Inc (Director · May 3, 2007 – Apr 30, 2008 · Past)
Director · Aug 4, 2016 – Feb 3, 2021 · Past
Andrew Kucharchuk
Other companies: RRE Ventures Acquisition Corp. (Chief Financial Officer · Since at least Apr 29, 2026); Range Capital Acquisition Corp II (Chief Financial Officer · Since at least Oct 2, 2025); CERo Therapeutics Holdings, Inc. (Chief Financial Officer & Director · Since at least Oct 1, 2024); Chain Bridge I (Chief Financial Officer · Apr 1, 2024 – Apr 1, 2024 · Past); Adhera Therapeutics Inc. (Chief Executive Officer, Director · Jul 7, 2020 – Jul 7, 2020 · Past); OncBioMune Pharmaceuticals Inc (Director · May 9, 2018 – Jun 5, 2020 · Past)
Director · Since at least Aug 3, 2025
James Huang
Other companies: CASI Pharmaceuticals, Inc. (Director · Since at least Mar 18, 2026); Connect Biopharma Holdings Limited (Founding Partner of Panacea Venture · Since at least Mar 18, 2026); Atara Biotherapeutics, Inc. (Human Capital · Since at least May 16, 2025); Orion Biotech Opportunities Corp (Chief Executive Officer, Director · May 12, 2021 – May 17, 2023 · Past); Alaunos Therapeutics, Inc. (Director · Jul 20, 2020 – Jun 6, 2023 · Past)
Director · Dec 21, 2018 – Feb 22, 2023 · Past
John P. Hamill
Other companies: Aprea Therapeutics, Inc. (Senior Vice President and Chief Financial Officer · Since at least Jan 30, 2023); Trevena, Inc. (VP Fin,Princ Fin&Acct Officer · May 31, 2019 – May 31, 2019 · Past)
SVP & CFO · Jul 20, 2020 – Jul 26, 2022 · Past
Saundra Pelletier
Other companies: Aditxt, Inc. (Director · Since at least Jun 5, 2025); Evofem Biosciences, Inc. (Chief Executive Officer, President and Executive Director · Since at least Jan 17, 2018)
Director · Aug 13, 2024 – Aug 13, 2024 · Past
Craig Fraser
Other companies: Aegerion Pharmaceuticals Inc (Chief Operating Officer · Sep 3, 2012 – Apr 1, 2015 · Past)
President and CEO, Director · Jul 28, 2016 – Oct 8, 2024 · Past
Eric Curtis
Other companies: Aegerion Pharmaceuticals Inc (President, U.S. Commercial · Aug 26, 2015 – Aug 26, 2015 · Past)
SVP & COO · Mar 9, 2020 – Aug 23, 2023 · Past
Jed Latkin
Other companies: ProPhase Labs, Inc. (Chief Operating Officer · Jan 1, 2024 – Jan 1, 2024 · Past)
Director · Aug 13, 2024 – Aug 13, 2024 · Past
Jamie McAndrewVP, Controller, & CAO · Aug 24, 2023 – Aug 24, 2023 · Past
Mary B Esq TempletonSVP, Gen Counsel & Corp Sec · Dec 24, 2018 – May 22, 2020 · Past

Open People

Log in to ask 6ix AI your own questions about Windtree Therapeutics, Inc.